Zura Bio Limited (ZURA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Sandeep C. Kulkarni.
ZURA 을(를) 보유 IPO 날짜 2023-03-21, 30 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $371.93M.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
